$91.145
-5.095 (-5.59%)收盘时
ORKA 资讯
ORKA 事件
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
Oruka Therapeutics (ORKA) announced the appointment of Todd Edwards as chief commercial officer, effective August 24. Edwards joins Oruka from Arcutis Biotherapeutics (ARQT), where he served as executive VP and chief commercial officer.
Oruka Therapeutics Files $1B Mixed Securities Shelf
Oruka Therapeutics files $1B mixed securities shelf
Oruka CEO: ORKA-001 Enters Critical Phase
"The second quarter and recent months were highly productive as we advanced both of our co-lead programs toward a series of important readouts," said Lawrence Klein, Chief Executive Officer of Oruka. "With EVERLAST-B now fully enrolled and a Phase 3 program for ORKA-001 on the horizon, alongside the initiation of ORCA-SPLASH in HS, we are executing on our strategy to establish ORKA-001 and ORKA-002 as potentially best-in-class options across psoriatic disease and beyond. We look forward to multiple significant clinical catalysts over the coming quarters."
Oruka Therapeutics Shares Down 8.1% to $85.69
Oruka Therapeutics is down -8.1%, or -$7.60 to $85.69.
BTIG Analyst Sees AbbVie Acquiring Apogee as Positive
BTIG analyst Julian Harrison says AbbVie (ABBV) can leverage its existing dermatology channels and compete in atopic dermatitis beyond JAK inhibitors with an acquisition of Apogee Therapeutics (APGE). Johnson & Johnson (JNJ), Pfizer (PFE), and Novartis (NVS) have strong dermatology channels but no prominent commercial presence in atopic dermatitis yet, and therefore could also be interested in acquiring Apogee, the analyst tells investors in a research note. BTIG views the Financial Times' report of AbbVie's potential buyout of Apogee as positive for other spinouts from Paragon Therapeutics, including Jade Biosciences (JBIO), Oruka Therapeutics (ORKA), Spyre Therapeutics (SYRE), and Crescent Biopharma (CBIO). The firm has a Buy rating on Apogee Therapeutics with a $137 price target. The stock in premarket trading is up 54%, or $49.10, to $139.48.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。